Skip to main content
    P

    Palisade Bio Inc (PALI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.03
    -0.09 (-8.04%)

    Market Cap: $201.01M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Palisade Bio Inc (PALI) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Palisade Bio (PALI) to earn -$0.24 per share in the fiscal year ending Dec 31, 2026, on revenue of $500000. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 5 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.70, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy330.0%
    Buy770.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss.

    Fiscal year ending Dec 31, 2026
    -$0.24
    EPS consensus, revenue $500000
    Fiscal year ending Dec 31, 2027
    -$0.31
    EPS consensus
    Next report
    Mar 18, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.24-$0.24 to -$0.244$500000$500000 to $5000008
    Dec 31, 2027-$0.31-$0.40 to -$0.228N/AN/A8

    Quarterly Estimates

    The EPS consensus is -$0.07 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.07-$0.10 to -$0.0512
    Mar 31, 2027-$0.07-$0.08 to -$0.054

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 3 upward and 11 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202625
    Fiscal year ending Dec 31, 202715
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.23.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.24-$0.22-$0.22-$0.23-$0.23N/A
    Fiscal year ending Dec 31, 2027-$0.31-$0.28-$0.28-$0.28-$0.28N/A
    Quarter ending Mar 31, 2027-$0.07-$0.07-$0.07-$0.07-$0.07N/A

    Frequently Asked Questions About PALI

    What is the PALI stock forecast?

    Consensus analyst estimates put Palisade Bio's EPS at -$0.24 for the fiscal year ending Dec 31, 2026, on revenue of $500000. The consensus rating from 10 analysts is Buy.

    How do analysts rate PALI stock?

    Of 10 analysts covering Palisade Bio, 3 rate it Strong Buy, 7 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from PALI next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.24, with estimates from -$0.24 to -$0.24 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.31, with estimates from -$0.40 to -$0.22 from 8 analysts.

    What revenue do analysts expect from Palisade Bio next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $500000, with estimates from $500000 to $500000.

    How many analysts cover PALI?

    10 analysts rate Palisade Bio stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.